Status
NOT RECRUITING
Purpose
This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in refractory aggressive Non-Hodgkin Lymphoma (NHL).
Investigator(s)
David Miklos, M.D., Ph.D.
Blood and marrow transplant specialist,
Blood and marrow transplant specialist,
Hematologist,
Medical oncologist
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Michael Khodadoust
Medical oncologist,
Lymphoma specialist,
Cutaneous oncology specialist,
Hematologist
Assistant Professor of Medicine (Oncology) and of Dermatology
Hans-Christoph Becker
Contact us to find out if this trial is right for you.
CONTACT
Physician Referrals
(650) 723-0822